TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17566806

Group type: EXPERIMENTAL
Intervention: 20 mg ebastine daily (monotherapy)
Number of subjects: 4307

Group type: COMPARATOR
Intervention: Combination therapy (not specified)
Number of subjects: 4307
Study: 15020174

Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy alone or in combination with the Committed Quitters(R) program, and individual counseling (if applicable)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Psychosocial treatment in addition to patch therapy
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Free smoking cessation treatment offered in primary care settings
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Minority patients
Number of subjects: 1869
Study: 11695932

Group type: EXPERIMENTAL
Intervention: Teaching SCGs about safe sleep practices (2 teaching sessions during the third trimester).
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Teaching SCGs about safe sleep practices.
Number of subjects: 223
Study: 9161178

Group type: EXPERIMENTAL
Intervention: Electronic Thermography (ET)
Number of subjects: 328
Study: 1448398

Group type: EXPERIMENTAL
Intervention: Recent large-scale investigations
Number of subjects: 0
Study: 6736578

Group type: EXPERIMENTAL
Intervention: Psychosocial activation program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 31504950

Group type: EXPERIMENTAL
Intervention: Dietary threonine (d-Thr) at 110% of NRC recommendation
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Dietary threonine (d-Thr) at 120% of NRC recommendation
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Soybean meal (SBM) diet
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Threonine supplementation (10%)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Canola meal (CM) diet
Number of subjects: 900
Study: 29372191

Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fluoride gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CPP-ACP + fluoride
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (placebo paste)
Number of subjects: 36
Study: 27068690

Group type: EXPERIMENTAL
Intervention: Preventive health consultation focused on life coaching (111 patients)
Number of subjects: 218

Group type: COMPARATOR
Intervention: No preventive consultation (107 patients)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Patients who prioritized weight loss during consultation
Number of subjects: 218

Group type: COMPARATOR
Intervention: Patients without prioritization of weight loss
Number of subjects: 218
Study: 24789859

Group type: EXPERIMENTAL
Intervention: HE4 as a first-line screen (Arm 1)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: HE4 as a second-line screen (Arm 2)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Combined results from both arms
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Protocol-indicated surgery
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Recommendation for surgical consultation
Number of subjects: 1172
Study: 22252020

Group type: EXPERIMENTAL
Intervention: 30 mg of aspirin
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 300 mg of aspirin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 94
Study: 20080264

Group type: EXPERIMENTAL
Intervention: Toronto Stentless Porcine Valve (SPV)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Carpentier‐Edwards pericardial valve (CE)
Number of subjects: 99
Study: 16631177

Group type: EXPERIMENTAL
Intervention: Computer-aided self-instruction
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Face-to-face teaching
Number of subjects: 92

Group type: COMPARATOR
Intervention: Combination of both methods
Number of subjects: 92
Study: 16224050

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12171818

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 39

Group type: COMPARATOR
Intervention: Heliox
Number of subjects: 39
Study: 10091727

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 375 mg/m2 and levofolinic acid (1-FA) at 100 mg/m2 for 5 consecutive days with recombinant interferon-2b (IFN) at 3 MU/day for 7 days starting 2 days before chemotherapy administration.
Number of subjects: 204

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) at 375 mg/m2 and levofolinic acid (1-FA) at 100 mg/m2 for 5 consecutive days without recombinant interferon-2b (IFN).
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and levofolinic acid (1-FA) with IFN.
Number of subjects: 204

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) and levofolinic acid (1-FA) without IFN.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Patients with limited liver involvement (regardless of chemotherapy arm).
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Patients with massive liver involvement (regardless of chemotherapy arm).
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Patients with limited liver disease.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Patients without liver involvement.
Number of subjects: 204
Study: 7483775

Group type: EXPERIMENTAL
Intervention: Accelerated immunization schedule (Group A)
Number of subjects: 912

Group type: COMPARATOR
Intervention: Traditional immunization schedule (Group B)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 912
Study: 1685667

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Epanolol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blockers (Atenolol and Epanolol)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no drug treatment)
Number of subjects: 13
Study: 7112697

Group type: EXPERIMENTAL
Intervention: disodium cromoglycate, hyposensitization with an aluminiumhydroxide‐adsorbed allergen extract of timothy, tall meadow oat and orchard grass, or combinations thereof
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: disodium cromoglycate eye drops 2% and chlorpheniramine tablets 2 mg as supplementary treatment
Number of subjects: 58
Study: 31066135

Group type: EXPERIMENTAL
Intervention: Self-monitoring wrist-worn device
Number of subjects: 22

Group type: COMPARATOR
Intervention: Self-directed workbook
Number of subjects: 22
Study: 27879955

Group type: EXPERIMENTAL
Intervention: Hypobaric levobupivacaine (HL group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isobaric levobupivacaine (IL group)
Number of subjects: 40
Study: 27228641

Group type: EXPERIMENTAL
Intervention: Melatonin emulsion
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 24345444

Group type: EXPERIMENTAL
Intervention: Memantine (titrated to 10 mg twice daily)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 94
Study: 21924636

Group type: EXPERIMENTAL
Intervention: Tranexamic acid, 10 mg/kg bolus before surgery followed by 1 mg/kg/h infusion during surgery
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 63
Study: 19620954

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg per feeding tube)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17473078

Group type: EXPERIMENTAL
Intervention: Family and Medical Leave Act benefits
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Employer-provided leave benefits (>4 weeks)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Paid leave benefits
Number of subjects: 574

Group type: COMPARATOR
Intervention: No leave benefits
Number of subjects: 574
Study: 15111672

Group type: EXPERIMENTAL
Intervention: 5-HT1A receptor binding potential measured with PET and [Carbonyl-11C]WAY-100 635
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (14 controls)
Number of subjects: 14
Study: 11177010

Group type: EXPERIMENTAL
Intervention: Propofol, 0.5 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Droperidol, 20 microg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metoclopramide hydrochloride, 0.2 mg/kg
Number of subjects: 90
Study: 9674679

Group type: EXPERIMENTAL
Intervention: Dental Logic HP550 with regular brush head HP5924 (Philips, U.K.)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Braun Oral B Plaque Remover (D7) with dedicated orthodontic brush head OD5‐1 (Braun AG, Germany)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual dedicated orthodontic toothbrush (P35, Oral B Laboratories, Calif.)
Number of subjects: 60
Study: 7913731

Group type: EXPERIMENTAL
Intervention: MN rgp120 vaccine (100 micrograms, 300 micrograms, or 600 micrograms)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: MN rgp120 vaccine (three doses)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Alum adjuvant alone (control)
Number of subjects: 57
Study: 3422262

Group type: EXPERIMENTAL
Intervention: CNS prophylaxis with 1,800 cGy cranial irradiation (CRT) plus intrathecal (IT) methotrexate (MTX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IT MTX plus intravenous (IV) high-dose MTX (HDMTX)
Number of subjects: 40
Study: 31190322

Group type: EXPERIMENTAL
Intervention: Phenylephrine (50 µg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ephedrine (5 mg)
Number of subjects: 29
Study: 27322592

Group type: EXPERIMENTAL
Intervention: Genomic counseling (GC) within 1 month of report viewing
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group with access to counseling 3 months post-report viewing
Number of subjects: 199
Study: 25244665

Group type: EXPERIMENTAL
Intervention: Isonicotinic acid hydrazide (INH) 900 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Misoprostol 25 μg
Number of subjects: 150
Study: 23040783

Group type: EXPERIMENTAL
Intervention: Domestic imipenem cilastatin sodium 1.0 g intravenous drip, every 6-8 hours for 7-14 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Imported injection imipenem cilastatin sodium 1.0 g intravenous drip, every 6-8 hours for 7-14 days
Number of subjects: 68
Study: 19861362

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 17640599

Group type: EXPERIMENTAL
Intervention: Structured walking regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with no formal exercise program
Number of subjects: 100
Study: 16055833

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 270
Study: 12391945

Group type: EXPERIMENTAL
Intervention: Assistive technology given to patients treated in a stroke unit
Number of subjects: 249

Group type: COMPARATOR
Intervention: Assistive technology given to patients treated in a general medical ward
Number of subjects: 249
Study: 10623356

Group type: EXPERIMENTAL
Intervention: Leukocyte filtration during cardiopulmonary bypass
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no filtration)
Number of subjects: 31
Study: 7541190

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (0.05%) ointment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Base ointment
Number of subjects: 6
Study: 2132086

Group type: EXPERIMENTAL
Intervention: K-Mg aspartate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mg aspartate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 100
Study: 499960

Group type: EXPERIMENTAL
Intervention: Card-Dusodril 1/8 (0.5 mg digoxin)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Card-Dusodril 1/4 (1 mg digoxin)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenously applied digoxin (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Card-Dusodril 1/8 and 1/4
Number of subjects: 14
Study: 31164071

Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 739

Group type: COMPARATOR
Intervention: General population
Number of subjects: 739
Study: 28605527

Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA, 30 minutes for 10 consecutive days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 40
Study: 26696112

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sublingual midazolam (0.2mg/kg)
Number of subjects: 20
Study: 24779025

Group type: EXPERIMENTAL
Intervention: Silorane-based composite (Filtek P90/P90 System Adhesive)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Methacrylate-based resin composite (Quixfil/Prime &Bond NT)
Number of subjects: 78
Study: 22469098

Group type: EXPERIMENTAL
Intervention: AZD2066 13 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AZD2066 2 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AZD2066 6 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 21032979

Group type: EXPERIMENTAL
Intervention: Orofacial myofunctional therapy (OMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Occlusal splint (OS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control group (SC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Asymptomatic group (AC)
Number of subjects: 30
Study: 18591167

Group type: EXPERIMENTAL
Intervention: Walking exercise intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 16091788

Group type: EXPERIMENTAL
Intervention: Aerobic conditioning during the second and third trimesters
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 28
Study: 11808830

Group type: EXPERIMENTAL
Intervention: Neoral (175 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sandimmune (300 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cmax of cyclosporine
Number of subjects: 24
Study: 10073243

Group type: EXPERIMENTAL
Intervention: 0.625 mg droperidol
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 2.5 mg droperidol
Number of subjects: 184

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 184
Study: 7750190

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) at an initial dosage of 2 IU/m2 body surface/day, increased if height velocity increment was less than 2 cm/year
Number of subjects: 55

Group type: COMPARATOR
Intervention: untreated control group with ISS
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: rhGH treatment in isolated GH deficiency (GHD) group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ISS group
Number of subjects: 55

Group type: COMPARATOR
Intervention: untreated controls
Number of subjects: 55
Study: 2115156

Group type: EXPERIMENTAL
Intervention: Inhaled disodium cromoglycate (DSCG) 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol 200 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: No premedication (test A)
Number of subjects: 12
Study: 6988171

Group type: EXPERIMENTAL
Intervention: 200 mg trimebutine 3-times daily for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg trimebutine 3-times daily for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 mg mebeverine 4-times daily
Number of subjects: 0
Study: 31638682

Group type: EXPERIMENTAL
Intervention: Fluoxetine (n=75)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (n=71)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Fluoxetine vs Placebo
Number of subjects: 146
Study: 29132733

Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply (energy, amino acids, lipids, long‐chain polyunsaturated fatty acids, vitamin A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard nutrient supply (control group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard nutrient supply)
Number of subjects: 50
Study: 26047808

Group type: EXPERIMENTAL
Intervention: Integrated Bipolar Parenting Intervention (IBPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 23622019

Group type: EXPERIMENTAL
Intervention: Head of bed elevation (HBE) at 45°
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pressure-controlled ventilation
Number of subjects: 200
Study: 20589679

Group type: EXPERIMENTAL
Intervention: Combination of hydroxyurea and imatinib
Number of subjects: 101

Group type: COMPARATOR
Intervention: Hydroxyurea monotherapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PDGFRα positive glioblastoma
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PDGFRα expression
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PDGFRα phosphorylation
Number of subjects: 101
Study: 19526158

Group type: EXPERIMENTAL
Intervention: Esmolol infusion (RP‐E)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil infusion (RP)
Number of subjects: 40
Study: 17920639

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control substance
Number of subjects: 80
Study: 16125218

Group type: EXPERIMENTAL
Intervention: Walking, resistance training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (diet only)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined groups (walking, resistance training, control)
Number of subjects: 90
Study: 12010224

Group type: EXPERIMENTAL
Intervention: Patients with Crohn's disease (CD)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Patients with a functioning colon
Number of subjects: 57
Study: 10450621

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral bibliotherapy (BT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral bibliotherapy (BT) with weekly phone consultations
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 54
Study: 8563376

Group type: EXPERIMENTAL
Intervention: Physician's Workstation (PWS)
Number of subjects: 0
Study: 2528817

Group type: EXPERIMENTAL
Intervention: Computer-based interview system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional clerking by a doctor
Number of subjects: 50
Study: 321176

Group type: COMPARATOR
Intervention: Furosemide 40 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg/day + Triamterene 50 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg/day + Triamterene 100 mg/day
Number of subjects: 23
Study: 30977721

Group type: EXPERIMENTAL
Intervention: Vignette with overweight child and positive communication tone
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Vignette with overweight child
Number of subjects: 233
Study: 31083706

Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBHI) scheme
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Adequate knowledge of CBHI benefit packages
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Type of health facility visit
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Laboratory service provision
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Length of enrollment
Number of subjects: 528
Study: 27371341

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50 (LM50)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Insulin lispro mix 25 (LM25)
Number of subjects: 156
Study: 25515848

Group type: EXPERIMENTAL
Intervention: First-person narrative message with experiential information processing
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: First-person narrative message with rational information processing
Number of subjects: 138

Group type: COMPARATOR
Intervention: Statistical message with experiential information processing
Number of subjects: 138

Group type: COMPARATOR
Intervention: Statistical message with rational information processing
Number of subjects: 138
Study: 22744960

Group type: EXPERIMENTAL
Intervention: Screening questions printed on prescreener forms (PSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Just in time (JIT) printed materials to aid physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (physicians reminded to screen on printed worksheets)
Number of subjects: 0
Study: 20739147

Group type: EXPERIMENTAL
Intervention: Hormone therapy combined with hypocaloric parenteral nutrition (HPN) including recombinant human growth hormone, octreotide, and systemic insulin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard total parenteral nutrition and systemic insulin
Number of subjects: 100
Study: 19216734

Group type: EXPERIMENTAL
Intervention: Autologous cultured osteoblast injection
Number of subjects: 64

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 64
Study: 17502045

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0
Study: 15130633

Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 intraocular lens (IOL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sensar OptiEdge AR40e IOL
Number of subjects: 30
Study: 11574374

Group type: EXPERIMENTAL
Intervention: 100 microg intrathecal morphine (MS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 0.2 mL of 0.9% saline (normal saline; NS)
Number of subjects: 66
Study: 9270509

Group type: EXPERIMENTAL
Intervention: Butenafine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cream vehicle (control)
Number of subjects: 78
Study: 7930255

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2465687

Group type: EXPERIMENTAL
Intervention: Personal instruction
Number of subjects: 28

Group type: COMPARATOR
Intervention: Videocassette instruction
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 30550338

Group type: EXPERIMENTAL
Intervention: Articulatory rehearsal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attentional refreshing
Number of subjects: 0
Study: 28885479

Group type: EXPERIMENTAL
Intervention: 20% subcutaneous immunoglobulin (SCIG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Individualized training and support for self-infusion
Number of subjects: 15
Study: 25695181

Group type: EXPERIMENTAL
Intervention: Promotion of hand washing and once-weekly application of chlorhexidine-based body wash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incrementally increasing education- and hygiene-based measures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0